SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain and as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is trending amid mixed sentiments, with some traders expressing frustration over recent price action and perceived manipulation, while others point to upcoming developments like the Goliath testnet and the multichain wallet launch as potential catalysts. The community is actively debating the coin's utility and future prospects, with discussions ranging from short-term trading strategies to long-term investment theses. There's also discussion around the correlation between Onyxcoin and the broader crypto market.

Mannatech, Inc. engages in the development of nutritional supplements, topical and skin care products and weight-management products that target optimal health and wellness. Its product category includes integrative health, targeted health, wealth and fitness, skin care, essentials, and home. The company was founded by Marlin Ray Robbins and Samuel L. Caster in November 1993 and is headquartered in Flower Mound, TX.

Mannatech Inc

MTEX is trending due to its low float and recent price action, sparking community discussion about a potential squeeze. Traders are closely watching key breakout levels, anticipating a significant move if volume increases. The stock's history of rapid gains and recent after-hours activity is fueling speculation and interest.

1 dog can change your life

The 1DOG crypto is trending, with community members highlighting positive chart patterns and increased volume, especially among Phantom Wallet users. There's a strong sense of "meme energy" around the token, with many anticipating a potential moonshot similar to DOGE or SHIB. Community buzz emphasizes joining the "pack" and not missing out.

StarHeroes is the first-ever multiplayer space shooter game designed for esports. The game has been developed since 2021 by GameSwift's subsdiary STAR studio, and offers fast-paced multiplayer galactic battles. StarHeroes provides both web3 and web2 modes, making its innovative gameplay accessible to a wide range of players. The web3 mode is based on a single token $STAR as well as NFTs. The $STAR token has the following utilities:  -Purchase of in-game spaceships -Purchase of in-game fuel to increase the number of games that allow a player to earn $STAR  -Leveling-up of the player’s NFT Hero -Purchase of missions for the player’s NFT Hero -Purchase of a feature that reduces mission time for the player’s  NFT Hero -Staking -Airdrop based on the in-game leaderboard -Share in Real Yield from the StarHeroes game -Governance   StarHeroes is currently in closed beta available to a selected number of players. The Early Access version will be launched in Q1 2024, while the full version is scheduled for Q2 2024.

Starbase

Starbase (STAR) is trending amid community excitement, with some linking it to Elon Musk's Starbase and increased chatter on Twitch. Discussions revolve around its utility beyond trading and how to acquire the coin, while some users are pointing out it could be related to other projects.

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

ICP is trending as the community debates its future and potential amid discussions around its technology and recent price movements. Some investors express frustration and call it a "scam," while others see its current price as a buying opportunity, citing its underlying technology and AI capabilities. Community members are also closely watching for increased adoption and institutional interest as potential catalysts.

Numeraire

Numeraire is trending as traders discuss its potential, citing its limited supply and connection to AI. The community is speculating on possible price movements, noting the coin's behavior relative to broader market trends like Bitcoin. Some are pointing to its unique use case in crowdsourced machine learning for hedge funds, while others highlight previous price surges.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic ($LUNC) is trending amidst community discussions about its price action and potential for recovery, with some holders expressing frustration over recent dips. Despite concerns, some community members remain optimistic, discussing potential future pumps and the impact of projects aimed at reviving the ecosystem. The conversation also includes broader market factors and the possible influence of external events.

Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. It utilizes Artificial Intelligence to assist in quality control processes that flag spectroscopy data indicative of a poor MRS study. It offers NOCISCAN Suite, a revolutionary software suite that works with existing high field Magnetic Resonance systems and Magnetic Resonance Spectroscopy pulse sequence packages using an optimized protocol to conduct MRS exams of lumbar discs. The company was founded by James C. Peacock, David S. Bradford, and Jeffrey Lotz in 2008 and is headquartered in Broomfield, CO.

Aclarion Inc

Aclarion ($ACON) is trending due to community speculation around its low float and potential for significant upside, with some eyeing it as a "monster potential" play. Discussions also involve potential catalysts like news from a presentation and speculation about buyouts, amid a broader market context of shifting investment sentiment related to China tariffs. Community members are actively discussing price targets and anticipating potential moves, both bullish and bearish.

Assemble’s AI agent, News3(NS3), was developed with the goal of revolutionizing Web 3.0 journalism. NS3 delivers crypto and global economic trends quickly and clearly, and leverages advanced AI reasoning capabilities to analyze these trends, enabling market participants to make data-driven decisions. In particular, NS3 utilizes OpenAI’s latest reasoning model as its core engine to analyze crypto and economic trends, providing a range of insights including market psychology, past case analysis, future predictions, ripple effects, and investment strategies in 12 languages.

Assemble Protocol

Assemble Protocol ($ASM) is trending as traders discuss its potential within the AI crypto sector, with some anticipating a breakout and highlighting its low market cap. Community members are actively debating potential catalysts, including a possible Binance listing and new developments, while others express frustration with price volatility. Some users cite whale activity and technical indicators as reasons for optimism, while others remain skeptical.

Coupang, Inc. engages in the provision of retail, restaurant delivery, video streaming, and fintech services to customers around the world under brands that include Coupang, Coupang Eats, Coupang Play, and Farfetch. It operates through the Product Commerce and Developing Offerings segments. The Product Commerce segment consists of the company's core retail and marketplace offerings and Rocket Fresh, its fresh grocery category offering. It also includes advertising products associated with these offerings. The Developing Offerings segment covers the company's more nascent offerings and services including: Coupang Eats, a restaurant ordering and delivery service in Korea, Coupang Play, an online content streaming service in Korea, fintech services, retail operations in Taiwan, as well as advertising products associated with these offerings. It also includes Farfetch, a global luxury fashion marketplace. The company was founded by Bom Kim in 2010 and is headquartered in Seattle, WA.

Coupang Inc - Ordinary Shares - Class A

Coupang Inc 

Coupang is trending as investors discuss its potential expansion into the U.S. e-commerce market, building on its success in South Korea; however, some analysts caution about e-commerce competition and its current valuation. The community is actively evaluating options strategies and discussing the company's growth prospects in AI and international markets.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper PR...

Jasper Therapeutics faced a wave of downgrades Monday after disclosing that a compromised drug product lot disrupted results in multiple cohorts of its Phase 1b/2a BEACON study evaluating briquilimab for chronic spontaneous urticaria (CSU), a skin allergy.BMO Capital cut the stock to 'Market Perform' from 'Outperform' and slashed its price target to $4 from $15, citing uncertainty caused by manufacturing issues that made it “challenging to separate the signal from the noise.”Cantor Fitzgerald also downgraded the shares to 'Neutral' from 'Overweight', saying the update “introduced uncertainty for clinical trial execution and development timelines.”&nbsp;The firm said it would wait for clarity on future Phase 2b regimens and timelines before re-engaging.William Blair issued a similar downgrade to 'Market Perform' from 'Outperform', flagging a lack of clarity around funding and concerns over the inactive drug lot, which also led Jasper to halt briquilimab development in asthma.&nbsp;The company confirmed that the affected batch was used in all patients in its ETESIAN asthma study.BTIG reduced its price target to $20 from $64 but maintained a 'Buy' rating, calling briquilimab “safe and active” with “compelling efficacy,” despite the paused asthma trial and delayed Phase 2b CSU start, now expected mid-2026.H.C. Wainwright dropped its target to $20 from $40 and retained a 'Buy' rating, citing the “surprising update” on the affected cohorts.&nbsp;The research firm shifted U.S. launch estimates for CSU and chronic inducible urticaria to 2030 and 2031, respectively, and now models a $5 million capital raise.Jasper said the affected cohorts — 240 mg Q8W and 240 mg loading dose plus 180 mg Q8W — showed little to no clinical response, with 10 of 13 patients dosed from the compromised batch.&nbsp;The company plans to replace the products for those patients and enroll 10–12 more across both cohorts. New data is expected in the fourth quarter.Across other cohorts, briquilimab produced deep and durable disease control.&nbsp;In the 240 mg and 360 mg single-dose groups, 8 of 9 participants achieved a complete response, with strong reductions in UAS7 and tryptase levels.&nbsp;Results from the open-label extension study also showed promising efficacy.Jasper is halting asthma and SCID development and may restructure to cut costs and extend its runway.However, retail sentiment for&nbsp;<a href="https://stocktwits.com/symbol/JSPR">Jasper Therapeutics</a> on Stocktwits was ‘extremely bullish’ amid ‘extremely high’ message volume.One user said Jasper looked oversold and predicted a move above $5, calling the reaction to the update an overreaction to 90% good news.<stembedurl>https://stocktwits.com/trt102967/message/620133879</stembedurl>Another user compared the situation to&nbsp;<a href="https://stocktwits.com/symbol/CAPR/news">Capricor Therapeutics</a> , which dropped last month after reports that&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/capricor-stock-slumps-on-report-of-key-fda-exec-removal/chlxVk2RRPt">two key FDA officials</a> overseeing the company’s cell therapy application were placed on administrative leave.<stembedurl>https://stocktwits.com/jlove0303/message/620128019</stembedurl>Jasper Therapeutics’ stock has declined 85.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Jasper Therapeutics (JSPR) is investigating a compromised drug batch in its briquilimab skin allergy trial/ Photo credit: Getty Images

Jasper Therapeutics Gets Hit With Downgrades Over Faulty Batch Of Skin Allergy Drug; Retail Sees ‘Overreaction’

The company flagged that 10 of 13 patients in two dosing cohorts received a compromised batch of briquilimab, leading to muted results.

Equity

Futures Slump As Yields, Dollar Soar

Futures Slump As Yields, Dollar Soar

 US equity futures were already rolling over following yesterday's momentum-driven rout, when a the latest report out of CNN (a polar opposite to the...

Why Is Chronic Disease-Focused Jasper Therapeutics Stock Trading Higher On Monday?

Jasper Therapeutics' SPOTLIGHT study reports 93% clinical response in cold urticaria and symptomatic dermographism. The 120mg dose showed 83% complete response and no severe adverse events. Full data...

Optimistic Buy Rating for Jasper Therapeutics as Briquilimab Shows Promising Trial Progress

TD Cowen analyst Yaron Werber has maintained their bullish stance on JSPR stock, giving a Buy rating today. Yaron Werber has given his Buy rating d...

Buy Rating for Jasper Therapeutics: Clinical Progress and Financial Stability Signal Strong Potential

Analyst Tim Chiang of Capital One Financial assigned a Buy rating on Jasper Therapeutics (JSPR Research Report), retaining the price target of $5...

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Jasper Therapeutics (JSPR)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Gilead Sciences (GILD Research Report) and Jasper Therapeutics...

TD Cowen Remains a Buy on Jasper Therapeutics (JSPR)

TD Cowen analyst Yaron Werber maintained a Buy rating on Jasper Therapeutics (JSPR Research Report) today. The company's shares closed yesterday...

Buy Rating for Jasper Therapeutics: Promising Pipeline and Market Disruption Potential with Briquilimab

Jasper Therapeutics (JSPR) has received a new Buy rating, initiated by BTIG analyst, Justin Zelin. Justin Zelin has given his Buy rating due to a c...

Jasper Therapeutics initiated with bullish view at Evercore ISI, here's why

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. It focuses on the development and commercialization of safer, stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company was founded by Judith Shizuru and Susan Prohaska in March 2018 and is headquartered in Redwood City, CA.

Jasper Therapeutics Inc

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$1.21	--	--	N/A
Q2 '25	-$1.33	-$1.74	-31.19%	MISSED
Q1 '25	-$1.35	-$1.41	-4.63%	MISSED
Q4 '24	-$1.25	-$1.62	-29.17%	MISSED
Q3 '24	-$1.07	-$1.24	-15.75%	MISSED

JSPR
Jasper Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest JSPR News

JSPRJasper Therapeutics Inc